Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAM NASDAQ:DSGN NYSE:OGN NASDAQ:RLAY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$32.68-8.8%$31.72$15.60▼$38.26$3.36B2.182.47 million shs2.83 million shsDSGNDesign Therapeutics$15.19-1.5%$12.74$3.76▼$17.25$948.72M1.58958,156 shs836,506 shsOGNOrganon & Co.$13.52+0.2%$13.43$5.69▼$13.60$3.55B1.542.26 million shs3.02 million shsRLAYRelay Therapeutics$20.00-3.6%$15.30$3.03▼$20.79$3.83B1.674.37 million shs3.19 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics0.00%-6.06%+11.12%+19.14%+52.28%DSGNDesign Therapeutics0.00%-2.88%+44.25%+24.92%+264.27%OGNOrganon & Co.0.00%-0.37%+0.30%+51.99%+35.69%RLAYRelay Therapeutics0.00%+7.24%+40.45%+33.87%+424.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$32.68-8.8%$31.72$15.60▼$38.26$3.36B2.182.47 million shs2.83 million shsDSGNDesign Therapeutics$15.19-1.5%$12.74$3.76▼$17.25$948.72M1.58958,156 shs836,506 shsOGNOrganon & Co.$13.52+0.2%$13.43$5.69▼$13.60$3.55B1.542.26 million shs3.02 million shsRLAYRelay Therapeutics$20.00-3.6%$15.30$3.03▼$20.79$3.83B1.674.37 million shs3.19 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics0.00%-6.06%+11.12%+19.14%+52.28%DSGNDesign Therapeutics0.00%-2.88%+44.25%+24.92%+264.27%OGNOrganon & Co.0.00%-0.37%+0.30%+51.99%+35.69%RLAYRelay Therapeutics0.00%+7.24%+40.45%+33.87%+424.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 2.73Moderate Buy$46.8543.35% UpsideDSGNDesign Therapeutics 2.88Moderate Buy$16.508.62% UpsideOGNOrganon & Co. 1.71Reduce$11.40-15.65% DownsideRLAYRelay Therapeutics 3.00Buy$23.7318.64% UpsideCurrent Analyst Ratings BreakdownLatest DSGN, BEAM, RLAY, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026BEAMBeam Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.007/8/2026RLAYRelay Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$28.007/7/2026BEAMBeam Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.007/6/2026RLAYRelay Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/26/2026RLAYRelay Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $26.005/26/2026RLAYRelay Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $28.005/21/2026BEAMBeam Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.005/20/2026RLAYRelay Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/20/2026RLAYRelay Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$21.00 ➝ $27.005/20/2026RLAYRelay Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$19.00 ➝ $21.005/19/2026RLAYRelay Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$26.00(Data available from 7/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$139.74M24.06N/AN/A$12.20 per share2.68DSGNDesign TherapeuticsN/AN/AN/AN/A$3.73 per shareN/AOGNOrganon & Co.$6.22B0.57$5.78 per share2.34$2.89 per share4.68RLAYRelay Therapeutics$15.35M249.63N/AN/A$3.27 per share6.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$79.99M-$0.68N/AN/AN/A-39.66%-29.00%-22.61%8/4/2026 (Estimated)DSGNDesign Therapeutics-$69.79M-$1.20N/AN/AN/AN/A-33.07%-31.29%8/6/2026 (Estimated)OGNOrganon & Co.$187M$0.9314.533.931.253.99%99.95%6.22%8/4/2026 (Estimated)RLAYRelay Therapeutics-$276.48M-$1.57N/AN/AN/AN/A-43.94%-40.11%8/6/2026 (Estimated)Latest DSGN, BEAM, RLAY, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026DSGNDesign Therapeutics-$0.36N/AN/AN/AN/AN/A8/6/2026Q2 2026RLAYRelay Therapeutics-$0.41N/AN/AN/A$0.96 millionN/A8/4/2026Q2 2026BEAMBeam Therapeutics-$1.1064N/AN/AN/A$16.37 millionN/A8/4/2026Q2 2026OGNOrganon & Co.$0.87N/AN/AN/A$1.57 billionN/A5/7/2026Q1 2026BEAMBeam Therapeutics-$1.0278-$0.91+$0.1178-$0.91$10.98 million$31.74 million5/5/2026Q1 2026RLAYRelay Therapeutics-$0.35-$0.41-$0.06-$0.41$5.58 million$3.00 million4/30/2026Q1 2026OGNOrganon & Co.$0.83$0.71-$0.12$0.55$1.49 billion$1.46 billion4/28/2026Q1 2026DSGNDesign Therapeutics-$0.36-$0.29+$0.07-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam TherapeuticsN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.59%N/A8.60%N/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ALatest DSGN, BEAM, RLAY, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2026OGNOrganon & Co.quarterly$0.020.6%5/11/20265/11/20266/11/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam Therapeutics0.0916.9916.99DSGNDesign TherapeuticsN/A22.2822.28OGNOrganon & Co.9.471.971.42RLAYRelay TherapeuticsN/A22.1322.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%DSGNDesign Therapeutics56.64%OGNOrganon & Co.77.43%RLAYRelay Therapeutics96.98%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics3.80%DSGNDesign Therapeutics17.10%OGNOrganon & Co.1.62%RLAYRelay Therapeutics5.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics510102.88 million98.97 millionOptionableDSGNDesign Therapeutics4062.46 million51.78 millionOptionableOGNOrganon & Co.10,000262.61 million258.36 millionNot OptionableRLAYRelay Therapeutics330191.59 million181.93 millionOptionableDSGN, BEAM, RLAY, and OGN HeadlinesRecent News About These CompaniesSanjiv Patel Sells 48,199 Shares of Relay Therapeutics (NASDAQ:RLAY) StockJuly 10 at 4:29 AM | americanbankingnews.comRelay Therapeutics (NASDAQ:RLAY) Insider Sells $162,028.60 in StockJuly 9 at 6:51 AM | insidertrades.comRelay Therapeutics (NASDAQ:RLAY) Coverage Initiated by Analysts at JPMorgan Chase & Co.July 9 at 3:14 AM | americanbankingnews.comRelay Therapeutics (NASDAQ:RLAY) Insider Donald Bergstrom Sells 8,660 Shares of StockJuly 8, 2026 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) CFO Sells 17,717 Shares of StockJuly 8, 2026 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) CEO Sells $943,736.42 in StockJuly 8, 2026 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Insider Sells $954,500.00 in StockJuly 5, 2026 | americanbankingnews.comInsider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells 50,000 Shares of StockJuly 3, 2026 | insidertrades.comRelay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past YearJune 29, 2026 | fool.comRelay Therapeutics (NASDAQ:RLAY) Insider Sells 93,456 Shares of StockJune 25, 2026 | insidertrades.comRelay Therapeutics (RLAY) is One of the Best AI Driven Biotech Stocks, Here is WhyJune 11, 2026 | insidermonkey.comRelay Therapeutics Expands Authorized Shares at 2026 MeetingJune 9, 2026 | tipranks.comRelay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comRelay Therapeutics, Inc. (RLAY) Presents at Jefferies Global Healthcare Conference 2026 TranscriptJune 3, 2026 | seekingalpha.comRelay Therapeutics to Participate in Two Upcoming Investor Conferences in JuneMay 27, 2026 | globenewswire.comRelay Therapeutics, Inc. (RLAY) Presents at ISSVA World Congress 2026: The Latest in Vascular Anomalies - SlideshowMay 22, 2026 | seekingalpha.comRelay Therapeutics (RLAY) Is Up 6.9% After Follow-On Offering And Early Zovegalisib Data ReleaseMay 22, 2026 | finance.yahoo.comRelay Therapeutics prices $275M public offering of common stock at $12/shareMay 21, 2026 | msn.comRelay Therapeutics: Encouraging Data, Competitive Risks (Downgrade)May 21, 2026 | seekingalpha.comRLAY stock declines pre-market after $175M offering — despite fresh bullish calls on Relay's zovegalisibMay 21, 2026 | msn.comRelay Therapeutics Prices Underwritten Public Offering of Common Stock Raising Approximately $275 MillionMay 20, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDSGN, BEAM, RLAY, and OGN Company DescriptionsBeam Therapeutics NASDAQ:BEAM$32.68 -3.14 (-8.77%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$32.52 -0.16 (-0.47%) As of 07/10/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Design Therapeutics NASDAQ:DSGN$15.19 -0.23 (-1.49%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$15.14 -0.05 (-0.33%) As of 07/10/2026 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Organon & Co. NYSE:OGN$13.52 +0.03 (+0.19%) Closing price 07/10/2026 03:59 PM EasternExtended Trading$13.52 0.00 (0.00%) As of 07/10/2026 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Relay Therapeutics NASDAQ:RLAY$20.00 -0.75 (-3.61%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$20.08 +0.08 (+0.40%) As of 07/10/2026 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Why "Big Short" Investor Michael Burry Sees Upside in Beaten-Down Sportbook Stocks Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
